Screening of the cBioPortal for Cancer Genomics (http://www.cbioportal.org/public-portal/) indicates amplification of MRCKA (CDC42BPA) in 13–25% of invasive breast cancer while TLK2 is amplified in 10% of invasive breast cancer and 25% of adenoid cystic breast cancer. This evidence concerns the gene CDC42BPA and invasive breast carcinoma.